test

The Authority

The Authority

The Authority

Flow Forward Closes $1.3 Million of Additional Series A Financing

Human Health published Tue, 2015-05-26 10:53

 OLATHE, Kan. - May 18, 2015 - Flow Forward Medical Inc. (Flow Forward), an early-stage company focused on improving outcomes for hemodialysis patients through the rapid creation of high-quality vascular access sites, today announced that it has closed a $1.3 million round of additional Series A financing, led by existing investor, the Kansas Bioscience Authority (KBA). Flow Forward previously raised $4.4 million in Series A funding, bringing the total in equity funding raised to date to approximately $5.7 million. Series A proceeds will be used to continue the development of Flow Forward's Arteriovenous Fistula Eligibility (AFE) System™, a small, minimally invasive blood pump system designed for temporary use to rapidly dilate peripheral veins through flow-mediated vascular remodeling prior to arteriovenous fistula (AVF) surgery.

 

Flow Forward also announced today that it will receive a $225,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The SBIR funding will be used to test peripheral vein dilation with the AFE System prior to AVF creation in a nonclinical model.

 

"Many of the two million patients on hemodialysis worldwide who undergo conventional surgical AVF creation each year experience vascular access site failure, which is associated with increased morbidity. With its AFE System, Flow Forward is addressing issues known to contribute to AVF failure," said Tom Krol, Managing Director at KBA and a member of Flow Forward's board of directors. "In early studies conducted in a challenging nonclinical model, the company has shown much more rapid vein dilation, large increases in blood flow and a significant reduction in vein wall scarring, when compared with conventional AVF creation. We believe that the AFE System has the potential to drive broad increases in AVF eligibility as well as large reductions in AVF failure."

 

Flow Forward also announced today the appointment of Kurt Dasse, PhD, to its board of directors. Dasse has spent nearly three decades conducting cardiovascular research and developing products to treat heart, lung and kidney diseases. He is currently President and CEO of GeNO LLC, a biopharmaceutical company developing next-generation delivery systems for inhaled nitric oxide, a pharmacologic blood vessel dilator. He was previously President and CEO of Levitronix LLC, a developer and manufacturer of rotary blood pump systems for cardiopulmonary support that was acquired by Thoratec Corporation in 2011.

 

"I am pleased to have additional financial resources from KBA and the NIH's SBIR program to accelerate the development of the AFE System. I also welcome Kurt to our Board. His decades of industry experience and deep domain experience in cardiovascular biology and physiology will be invaluable as we work to realize our goal of providing physicians more and better options when creating vascular access sites for hemodialysis patients," said F. Nicholas Franano, MD, President and CEO of Flow Forward.

 

 

 

 

 

 

 

 

Share

Metactive Closes $2 Million of Additional Series A Financing

Human Health published Mon, 2015-02-23 15:57

OLATHE, Kan. - Feb. 23, 2015 - Metactive Medical Inc. (Metactive), an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced that it has closed on $2 million of additional Series A financing, led by the Kansas Bioscience Authority (KBA), an existing Metactive investor. Proceeds will be used to continue the development of Metactive's novel embolic devices for occlusion of saccular aneurysms and peripheral arteries and veins. Metactive previously raised $5 million in Series A funding, bringing the total funding raised to date to $7 million.
 

"Metactive has shown immediate, complete and lasting occlusion of large saccular aneurysms with rapid endothelialization of the aneurysm neck in a challenging nonclinical model, as well as similarly robust performance with a peripheral occlusion device," said Tom Krol, Managing Director at KBA and a member of Metactive's board of directors. "Clinicians treat thousands of saccular aneurysms and peripheral arteries and veins each year. We believe that Metactive's devices have the potential to be better for patients, faster and easier for physicians to use, and less expensive for payers."

 

Metactive also announced today the appointment of David Ferrera to its board of directors. Ferrera is currently President and Chief Technology Officer of Blockade Medical and has 20 years of leadership experience in the medical device industry at several market-leading neurovascular firms, including MindFrame, Microvention and Micrus Endovascular.

 

"I am pleased to have the resources to accelerate the development of our novel, potentially life-saving products and to welcome David to our board to help us realize our goal of providing physicians faster, better and less expensive options for vascular occlusion," said F. Nicholas Franano, MD, President and CEO of Metactive.

 

About Peripheral Artery and Aneurysm Embolization

Embolization is a minimally invasive treatment that blocks the flow of blood in selected segments of arteries and veins, enabling physicians to divert blood away from cancerous tumors and other abnormal tissues, as well as from damaged or malformed segments of blood vessels. More than 150,000 peripheral vascular embolization procedures are performed each year worldwide using coils and vascular plugs. Similarly, more than 150,000 cerebral aneurysm embolization procedures are performed worldwide each year using coils and flow-diverting vascular stents. There is currently a need in these markets for endovascular embolization devices that can be placed quickly and easily, with a high degree of precision, and that result in immediate and lasting occlusion.

 

About Metactive Medical

Metactive is developing novel endovascular medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.

Share

Biova LLC announces new, second location in Kansas Bioscience Park

Human Health published Wed, 2014-09-24 10:57

Johnston, Iowa, USA—Biova LLC, the world leader for water soluble egg membrane ingredients, has expanded their cutting-edge technology into a new neighborhood.

The new Biova office at 10900 S.Clay Blair Blvd in Olathe, Kans., is located in the Venture Accelerator at the Kansas Bioscience Park, next to some of the leading—and fastest growing—science and technology businesses in the United States.

“Our expansion is so much more than elbow room,” said Matt Stegenga, Biova’s director of marketing. “There are great things happening at Biova. We wanted a scientific, collaborative community that understands the needs of growing technology companies. Kansas Bioscience Park checked all our boxes.”

The new Biova Olathe office will focus on managing the burgeoning product development and marketing operations for Biova’s egg membrane technologies and branded ingredients. Kathy Hockla, project manager, has been hired joining Stegenga in Biova's new Olathe offices.

About Biova:
Privately held and globally distributed, Biova is the market leader for water soluble egg membrane ingredients offering proven health benefits: BiovaFlex for joint health; BiovaDerm for skin care; and BiovaPlex® for animal health. Biova's patented water soluble process creates expanded delivery options for consumer products, including functional foods, beverages,lotions and more. Years of dedicated investment, ongoing scientific research and leading-edge technology are at the core of
these all-natural, ultra-pure, nutrient-rich ingredients. A focus on sustainable production, anchored by vertical integration with the largest U.S. egg producing and processing partners, assures Biova an almost unlimited supply of 100% U.S. domestic sourced raw material.

Share

FlexiLume Dental LED System Receives FDA Approval

Human Health published Mon, 2014-08-18 16:36

Mission, Kansas -  EMCI is proud to announce that the FlexiLume Dental LED System has received regulatory clearance for sale worldwide, including FDA approval and CE mark.


Peter Lucas, COO of EMCI, says, “The FlexiLume represents a paradigm shift in dental workflows that will improve doctor, hygienist, and patient experiences. We are very excited that we can now offer the product to dentists
worldwide, and we believe strongly that it will be very popular.”


“I believe that with this product we have achieved a whole new concept in operatory lighting systems. Access, visibility, and efficiency are very important procedural dependents for success within the operatory; the flexible extension arm delivers the light source directly where it is needed, and satisfies all of these elements. Placement of the light, curing tip, or transdental illumination on the tooth allows the clinician to achieve a “hands free” technique, and makes this system unbelievably easy to use. That alone, is worth the investment,” says Dr. Irwin Boe, inventor and founder of Innovative Products, Inc. Innovative Products, Inc., is a Kansas-based corporation with numerous inventions and patents, and dedicated to constant innovation in the field of dentistry.


James Lucas and Peter Lucas founded EMCI in 2006. Its focus is medical device innovation and development. The company has a solid history in the medical device industry and is currently developing and commercializing a wide array of new, cutting-edge technologies.  For more information: www.emci.co/flexilume.

 

Share

CritiTech and European Medical Contract Manufacturing Announce Collaboration

Human Health published Tue, 2014-08-05 09:34

LAWRENCE, KS – CritiTech, Inc., a growing drug delivery and development company, announced today that it has entered into a collaboration with European Medical Contract Manufacturing (EMCM) of Nijmegen, Netherlands, to develop tissue grafts coated with a variety of drugs using CritiTech’s proprietary supercritical fluid technology. The coated tissue grafts are being developed to provide effective and long-lasting antimicrobial control and rapid healing, especially in revision surgeries, to compensate for and correct failed implants.


“By combining EMCM’s eCOO® proprietary manufacturing process with CritiTech’s active pharmaceutical ingredients (API) coating technology, CritiTech and EMCM expect to produce tissue grafts that preserve their flexibility and maintain their structural and mechanical properties,” said Gary Clapp, CritiTech’s Vice President of Technical Operations. Coating EMCM’s tissue grafts with CritiTech’s supercritical fluid technology should produce unique benefits such as: (1) enabling the use of a wide range of APIs; (2) use of pure APIs; (3) delayed release of the APIs; and (4) incorporation of biodegradable release agents.


The goal of the collaboration between CritiTech and EMCM is to develop the first commercial tissue grafts coated with API using supercritical carbon dioxide. Initial results of the joint product development effort should be available later this year.

We are very excited about this opportunity and to be working with EMCM,” said CritiTech president Matthew McClorey. “They are a competent, focused and driven product development partner.”

This is the second major announcement from CritiTech over the last five weeks. On June 30th, CritiTech announced the successful completion of a Phase I Trial for its ovarian cancer drug, Nanotax®.

For more information about CritiTech, please visit www.crititech.com

 

Share

CritiTech Announces Positive Results from Phase I Trial of Nanotax® for Intraperitoneal Cancers

Human Health published Tue, 2014-07-01 09:04

LAWRENCE, KS – CritiTech, a growing drug delivery and development company, announced today positive results from the Phase I Trial of Nanotax® (“Trial”), a novel fine particle reformulation of paclitaxel to treat intraperitoneal cancers. The Trial, conducted at three clinical sites headed up by the National Cancer Institute Designated University of Kansas Cancer Center was designed to study the safety and pharmacokinetics in 21 patients with advanced peritoneal (“IP”) cancers.

“We are excited by the safety and pharmacokinetics outcomes from the Phase I Trial,” said Dr. Charles Decedue, Chief Scientific Officer at CritiTech. “The study results demonstrated that Nanotax® was very well tolerated, and there were no serious adverse events related to the drug. The data also showed evidence of high paclitaxel concentrations in the peritoneal cavity, extended drug release exposing tumors to higher concentrations of drug over a longer period of time, as well as substantially lower systemic exposure compared to intravenous injection of paclitaxel. With guidance from the U.S. Food and Drug Administration, we are looking forward to initiating the next steps to continue to advance Nanotax®.”

The safety and pharmacokinetic profile in the Phase I Trial is consistent with pre-clinical studies. In pre-clinical rat studies, Nanotax® had a ten-fold higher maximally tolerated dose compared to Taxol®. Delivered intraperitoneally in a mouse ovarian cancer model, Nanotax® significantly increased overall survival when compared to equal doses of Taxol®. In addition, substantially higher doses of Nanotax® compared to Taxol® could be delivered to the mice without noticeable toxicity.

About the Nanotax® Phase I Trial
Phase I Trial patients had relapsed solid IP tumors and adequate organ function. The primary malignancy was ovarian cancer (74%). Nanotax® was administered IP as a bolus injection after 500 ml saline followed by IP administration of up to 2 L of saline. The pharmacokinetics of IP administered Nanotax® were characterized in plasma and peritoneal fluid. Patients were treated at dose levels from 50 – 275mg/m2 every 28 days. Treatment was well tolerated. Pharmacokinetic data demonstrate significant, persistent IP exposure to Nanotax® at higher concentrations (~1,000X) compared to intravenous paclitaxel administration, with minimal systemic exposure and enhanced safety compared to Taxol®.
About Nanotax®


Nanotax® has been developed for the treatment of intraperitoneal carcinomas (e.g., ovarian cancer, pancreatic cancer, colorectal, liver, bladder, etc.) and is delivered via direct injection into the abdominal cavity. Nanotax®, is a Cremophor®-free, fine-particle reformulation of paclitaxel, developed by CritiTech using its proprietary fine-particle drug reformulation and production technology. Cremophor®, polyethoxylated castor oil, is the excipient used to deliver the poorly soluble paclitaxel (Taxol®) that is delivered intravenously. Some of the side effects associated with Taxol® include nausea, vomiting, diarrhea, blurred vision, difficulty swallowing, painful or difficult urination, ulcers or sores in the mouth, thinned or brittle hair, pain in the joints of the arms or legs, tingling in the hands or toes, unusual bruising or bleeding/pain/ redness/swelling/ blistering/infection/swelling at the injection site, change in normal bowel habits, fever, chills, cough, sore throat, difficulty swallowing, dizziness, shortness of breath, exhaustion, skin rash, itching, facial flushing, et. al. (see www.drugs.com).
CritiTech’s goal is to develop Nanotax® as a safer, better tolerated and more effective formulation of paclitaxel than those available on the market today

About CritiTech
CritiTech, Inc. is a drug delivery and development company focused on using the company’s proprietary Supercritical Fluid (“SCF”) Technology to help its clients and partners develop and manufacture unique and differentiated drugs and medical devices. CritiTech specializes in optimizing the delivery of challenging drug substances, potent molecules and poorly soluble compounds. By combining its SCF Technology with its ability to simplify formulations, CritiTech can expand and improve the drug delivery options for oral, injectable, and inhaled drugs, as well as implantable devices.

Share

Metactive Wins First Prize at the Medical Device Entrepreneur's Forum at the ASAIO 60th Annual Conference

Human Health published Tue, 2014-06-24 08:59

OLATHE, Kan.  Metactive Medical, Inc. ("Metactive") announced that it was awarded top prize in a business plan competition hosted by the Medical Device Entrepreneur's Forum, a special session held on June 20, 2014 at the ASAIO 60th Annual Conference in Washington, DC. F. Nicholas Franano, MD, President and Chief Executive Officer of Metactive, presented to a group of experts in medical device development and commercialization, venture capital, reimbursement, and regulatory affairs. Metactive placed first among a selected group of companies with innovative medical devices used for the treatment or diagnosis of disease.

 

"The role that ASAIO has played in bringing together a diverse group of creative and entrepreneurial scientists, engineers, clinicians, and industry representatives has been a critical factor in the development of a wide range of life saving technologies that we rely on today, including hemodialysis machines, ventricular assist devices, and extracorporeal membrane oxygenators, among many others," said Dr. Franano. "I know of no better place where medical device inventors and innovators can find fellow travelers, collaborators and friends. I'm honored that Metactive was recognized by this group."

 

About ASAIO

ASAIO (formerly known as the American Society for Artificial Internal Organs) is a premier society founded in 1955 for physicians, scientists, engineers, and entrepreneurs dedicated to the continually evolving fields of artificial organs, medical devices, and tissue engineering. For more information visit www.asaio.com.

 

About Metactive Medical

Metactive is developing novel endovascular medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.

 

Share

IGXBio receives FDA approval to move forward with GenePro® clinical trials

Human Health published Tue, 2014-06-17 17:29

Lenexa, KS – IGXBio, Inc. has received approval from U.S. Food and Drug Administration (FDA) to begin human clinical trials of GenePro®, a DNA-based HIV vaccine.

Jim Laufenberg, Co-Founder and CEO of IGXBio stated, “This is a very exciting time for the company, and achieving this milestone allows us to proceed with first in-man studies in HIV positive individuals”.
 
IGXBio, formerly known as Immunogenetix Therapeutics, has also received angel investment from the Mid-America Angels and funding from the State of Kansas. To date, the company has received $4,625,000 in capital funding to develop its DNA therapies. In addition, the National Institutes of Health has provided $21,000,000 in grants to the development of GenePro®.


About IGXBio
IGXBio, Inc. is a clinical-stage biotechnology company developing DNA therapies for the treatment of viral infections with a focus on HIV. The company's proprietary lead candidate, GenePro®, has published efficacy studies in non-human primates with promising results. The incidence for HIV/AIDS is estimated at 1.1 million in the U.S. and growing. Due to drug resistance developing in the use of current antiretroviral drug therapy, along with an increase in serious adverse effects, there is a large demand for immune modulating drugs such as GenePro®. For more information please visit: IGXBio.com.

 

Share

Flow Forward Announces Spinout from Novita

Human Health published Thu, 2014-05-29 10:02

Flow Forward Medical, Inc., an early-stage medical device company focused on improving outcomes for hemodialysis patients through the rapid creation of high-quality vascular access sites, today announced that it has launched operations as an independent company at the Venture Accelerator in the Kansas Bioscience Park in Olathe. Flow Forward was initially founded in 2011 as a subsidiary of Novita Therapeutics, LLC, a privately held life sciences incubator.
 

"Flow Forward is focused on developing the AFE System, which has the potential to substantially increase the number of hemodialysis patients using an arteriovenous fistula (AVF), the gold standard in vascular access sites," said F. Nicholas Franano, MD, chief executive officer of Flow Forward. "Currently, many patients are unable to get a functional AVF due to inadequate vein size and poor vein maturation, and we believe our system can help overcome these problems."
 

Hemodialysis is a lifesaving treatment for end-stage renal disease (ESRD) that requires the patient to have a vascular access site. The preferred type of site for hemodialysis patients is an AVF, due to improved patient survival, reduced complications and hospitalization rates, and large reductions in the cost of care when compared with other forms of access. However, nearly half of U.S. hemodialysis patients do not currently use an AVF for vascular access, primarily due to inadequate vein diameter and high rates of AVF failure.

Flow Forward's Arteriovenous Fistula Eligibility (AFE) System™ is a small, temporary, minimally-invasive blood pump designed to rapidly dilate peripheral veins through flow-mediated dilation prior to AVF surgery.  Use of the AFE System could increase patient eligibility for AVF and improve success rates after AVF surgery. In a recent presentation at the American Society of Nephrology annual meeting, Flow Forward reported results of a small pilot nonclinical study showing vein dilation 20 times faster and a large reduction in vascular scar tissue formation during vein maturation, when compared with traditional AVF creation.

“This represents real innovation,” said Tom Krol, Managing Director at the Kansas Bioscience Authority and a Flow Forward investor and director, “with the potential to deliver benefits to patients that would not have previously been thought possible.” “Successful development and commercialization of the AFE System could begin to alleviate some of the enormous burden that vascular access failure places on patients, health care providers, and payers”, said Krol, “and that makes the work at Flow Forward both an important effort and an attractive investment for KBA.”

 

About Flow Forward Medical

Flow Forward is developing a novel approach to rapidly establish high-quality vascular access sites for hemodialysis. The AFE System is a small, temporary, external blood pump designed to stimulate flow-mediated dilation to make more patients eligible for an arteriovenous fistula (AVF) and increase success rates after surgery. Establishment of a reliable AVF reduces morbidity and mortality in hemodialysis patients, as well as the overall cost of care. For additional information, please visit www.flowforwardmedical.com.

 

Share

Metactive Debuts Novel Embolization Technology

Human Health published Sun, 2014-03-23 10:03

Metactive Medical, Inc., an early-stage company focused on developing endovascular embolization devices for the treatment of neurovascular and peripheral vascular diseases, today presented new nonclinical data on one of its investigational devices at the Society of Interventional Radiology's (SIR) Annual Scientific Meeting. Metactive currently has two devices under development, and today's presentation focused on the company's device that addresses the cerebral aneurysm market. The company's chief executive officer, F. Nicholas Franano, MD, made an oral presentation entitled "Over-the-wire Device for Immediate, Complete and Durable Occlusion of Saccular Cerebral Aneurysms" during the "Arterial Aneurysms and Dissection" session at the meeting.
 

 

"Endovascular embolization of cerebral aneurysms with coils was a major advance when it was introduced more than 20 years ago," said Dr. Franano. "The technology that we are developing at Metactive builds upon that innovation by providing a next-generation device that has the potential to provide better patient outcomes, to be faster and easier for physicians to use, and to improve hospital profitability."
 

 

Physicians treat approximately 280,000 aneurysms per year worldwide using surgical clips, endovascular coils and flow-diverting stents. Current treatments are complex and costly, and do not consistently result in complete and permanent occlusion of aneurysms. At SIR today, Metactive presented findings from a recent pilot nonclinical study in which the company's cerebral aneurysm embolic device demonstrated immediate and complete mechanical occlusion of a large, terminal saccular aneurysm, as well as full endothelialization and sealing of the aneurysm neck at one month. By comparison, in the same aneurysm model, treatment using widely used conventional coils did not provide immediate and complete occlusion. Compared to coiling, the procedure to place Metactive's device took half as long, and the devices cost one-third as much. While Metactive has only completed a handful of nonclinical procedures to date, these excellent early results support further investigation.
 

 

"If Metactive can demonstrate that this new device can provide better clinical outcomes with much lower procedure time and complexity, and large reductions in cost, then I believe it has the potential to provide real value for patients, physicians, hospitals and payers -- especially for large aneurysms," said Kieran Murphy, MD, interventional neuroradiologist and professor of radiology at the University Health Network Toronto in Ontario, Canada, and director of clinical faculty at the Techna Research Institute.
 

Share

Health Outcomes Sciences Completes First Close of Series A Preferred Financing

Human Health published Wed, 2014-03-05 22:09

Kansas Bioscience Authority, Grayhawk Venture Fund II Lead Round

Health Outcomes Sciences Inc. (HOS), a leading health care IT company based in Overland Park, Kan., today announced that it has completed the first close of its Series A Preferred financing round. The company has raised $5 million in the first closing and expects to raise up to an additional $2 million of capital, bringing the round to $7 million.

The round, which is led by the Kansas Bioscience Authority (KBA) and Grayhawk Venture Fund II (GVFII), also includes a broad representation of existing angel investors. The funds will be used to grow sales of the company’s ePRISM® clinical decision support software, which provides evidence-based individualized risk models to physicians where they need them most, at the point of care.   

“We are thrilled to have KBA and Grayhawk join us in our pursuit to impact the cost-quality paradox in health care,” said Matt Wilson, HOS president and CEO. “HOS is among the first to capitalize on a huge market for technologies capable of personalizing patient analytics and applying them in direct clinical care. This round of funding will help us build on our early success in cardiology and extend our reach to other specialties.”

Keith Harrington, KBA managing director, said, “KBA is delighted to partner with the Health Outcomes Sciences team to accelerate the company’s sales growth and improve patient outcomes. This is a great example of a Kansas-based, world-class life sciences company doing important work throughout the U.S.”  

Brian Burns, GVFII partner, added, “HOS is at the leading edge of using big data for supporting medical decisions. We are excited to be a part of a company that can improve both health outcomes and cost containment in hospitals.”

Share

Metactive Announces Spinout from Novita

Human Health published Fri, 2014-02-21 08:56

Metactive Medical, Inc., an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced that it has launched operations as an independent company at the Venture Accelerator in the Kansas Bioscience Park in Olathe. Metactive was initially founded in 2012 as a subsidiary of Novita Therapeutics, LLC, a privately held medical device incubator. At the present time, the Company has two products under development.

 

Metactive's first product addresses the peripheral artery embolization market, where physicians perform about 180,000 procedures per year worldwide using vascular coils and plugs. In a recent pilot nonclinical study, Metactive's peripheral embolic product demonstrated immediate post-deployment vascular occlusion in all seven cases, while a leading competitive plug product did not demonstrate immediate occlusion in any of three cases. Metactive's product maintained complete occlusion in all cases at 28 days, while the same leading competitive product was unable to maintain occlusion in any cases.

 

"Clinicians who perform peripheral embolization have been asking for an over-the-wire embolic device on a microcatheter platform that is easy to use and can provide immediate, complete, and durable occlusion," said Metactive CEO, F. Nicholas Franano, MD. "We believe we have built a product that meets those specifications and are moving forward to make it available to physicians who want it and patients who need it."

 

Metactive's second product addresses the cerebral aneurysm market, where physicians treat about 280,000 aneurysms per year worldwide using surgical clips, vascular coils, and flow-diverting stents. In a pilot nonclinical study, Metactive's cerebral aneurysm embolic product demonstrated immediate occlusion of a large, terminal saccular aneurysm and full sealing and endothelialization of the aneurysm neck at one month. The Metactive product provided immediate and complete occlusion, which the widely used coil treatment did not provide in the same aneurysm model. Metactive's product also demonstrated a 50% reduction in procedure time and a 60% reduction in device cost when compared with coiling.

 

"Endovascular embolization of cerebral aneurysms with coils was a major advance when it was introduced more than twenty years ago," commented Dr. Franano. "The product we have developed at Metactive builds upon that innovation by providing a next-generation device that has the potential to be better for patients, faster and easier for physicians to use, and less expensive for payers."

 

"When managing life-threating situations, physicians need the best tools available to deal with the situation quickly and effectively," said Tom Krol, Managing Director at Kansas Bioscience Authority and a Metactive investor and member of the Board of Directors. "Metactive is developing new and highly effective devices to add to that the toolbox, ones we think physicians will reach for first in these situations."

 

Share

HDL, Inc. Acquires Exclusive U.S. License For Early Lung Cancer Detection Test From Oncimmune Ltd.

Human Health published Tue, 2013-10-29 14:52

Virginia-based Health Diagnostic Laboratory, Inc. will acquire and operate Oncimmune’s DeSoto, Kansas lab and become  the exclusive licensed U.S. provider of EarlyCDT®- Lung, the world’s first autoantibody test for early detection of lung cancer.

“KBA was an early investor in Oncimmune USA in 2006, investing $2 million in a convertible note to help the company establish its CLIA lab operation in De Soto, KS.  We are delighted at this outcome and look forward to the continued success of the EarlyCDT-Lung test,” said Keith Harrington, KBA Director of Commercialization.

“Oncimmune’s subsidiary in the U.S. has been building sales and awareness of the EarlyCDT-Lung test on a steady basis for the past few years,” said Geoffrey Hamilton-Fairley, Executive Chairman of Oncimmune Ltd. “By licensing our first test to HDL, we have secured access to a distribution channel that will deliver greater volume more quickly and at the same time provide sufficient revenues so that the company can accelerate the launch of our other early cancer detection tests.”

Lung cancer is the leading cause of cancer deaths among men and women in the U.S., taking the lives of more people each year than colon, breast, prostate, and pancreatic cancers combined. Lung cancer claims more than three times as many men as prostate cancer and nearly twice as many women as breast cancer. The American Cancer Society predicts that in 2013 there will be approximately 228,000 new cases of lung cancer diagnosed and nearly 160,000 lung cancer associated deaths

Oncimmune USA’s 25 employees will join the 740-employee HDL, Inc. and will remain in the De Soto location as of the closing date for the transaction.

Share

Subscribe Via RSS

Recent Blog Posts

By Sector

Bioenergy Animal Health Human Health

Archive

2014

2013

2012

2011